Core Viewpoint - Movano Health has received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement and late filing of its Form 10-Q for the quarter ended March 31, 2025 [1][2]. Group 1: Delisting Notice Details - The company was notified on July 7, 2025, that its common stock's closing bid price had fallen below $1.00 per share for 30 consecutive trading days, violating the Bid Price Requirement [2]. - The company is not eligible for any compliance period due to a reverse stock split that occurred within the prior year [2]. - Movano Health plans to request a hearing before a Nasdaq Hearings Panel to contest the delisting and intends to seek an extended stay of suspension during the hearings process [1][3]. Group 2: Company Background - Movano Health, founded in 2018, focuses on developing healthcare solutions that provide medical-grade data through wearable devices [4]. - The company's technologies aim to proactively monitor and manage health outcomes across various patient populations [5].

Samsung is exploring new wearable form factors such as earrings and necklaces | TechCrunch https://t.co/WQy959vjuL ...

In Brief Samsung released its first fitness-focused smart ring last year, adding to its stable of wearables that’s mostly comprised of smartwatches. The company is now looking to bolster its lineup with new wearables in different form factors, like glasses, earrings, and necklaces, CNN reported.Won-joon Choi, COO of Samsung’s mobile experience division, told CNN that the company wants to explore form factors that let users communicate and do things without needing their phones. “We believe it should be wea ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of fiduciary duty breaches by the board of directors following a class action complaint filed on June 20, 2025 [1] Company Overview - West Pharmaceutical Services, Inc. is a medical supplies company based in Exton, Pennsylvania, serving as a key supplier to the pharmaceutical, biotechnology, and generic drug industries [2] Allegations and Issues - The class action complaint alleges that West failed to disclose significant destocking issues in its high-margin High-Value Products portfolio, despite claiming strong visibility into customer demand [2] - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [2] - Margin pressures raised the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [2] - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2] Disclosure of Financial Issues - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [3] - West indicated that its SmartDose devices would be margin-dilutive in 2025 and mentioned plans to improve the device's economics [3] - Following this disclosure, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [3][5]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [5]. - It is claimed that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [5]. - The allegations include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [5]. Group 2: Financial Impact and Stock Performance - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [6]. - Following the announcement, West's stock price plummeted by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [7]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 between February 16, 2023, and February 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [3].

Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies [3] Financial Results Announcement - Kestra Medical Technologies will report its fourth quarter and fiscal year 2025 financial results on July 15, 2025 [1] - A conference call will be hosted by management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Details - A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website [2] - Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call [2]

Core Insights - Hapbee Technologies Inc. is expanding its Board of Directors by adding three senior leaders in technology, legal, and finance to support its growth phase and innovation efforts [1][2] - The company has revoked the Management Cease Trade Order (MCTO) following the filing of its 2024 audited annual financial statements, allowing its CEO and CFO to trade securities without restrictions [3] Group 1: Board Expansion - Ahsan Ashraf has been appointed to the Board as Chief Technology Officer, enhancing leadership as the company focuses on innovation and market expansion [1][2] - The Board will increase from eight to ten members to better manage the company's growing scale and complexity [2] - Mark Timm will step down from the Board after four years, with the CEO expressing gratitude for his contributions [3] Group 2: Revocation of MCTO - The revocation of the MCTO allows the company's CEO and CFO to trade securities freely, following the submission of required financial statements [3] - The MCTO was previously approved under National Policy 12-203 by the British Columbia Securities Commission [3] Group 3: Company Overview - Hapbee Technologies is a digital wellness company that specializes in bio-streaming wearables aimed at optimizing sleep, focus, mood, and recovery [4] - The company's technology delivers safe, non-invasive signals to promote well-being, all managed through a mobile app [4] Group 4: New Board Members - Kenneth S. Adessky joins as Corporate Counsel and Corporate Secretary, bringing extensive legal and regulatory expertise [6] - Rachid Lassal, CPA, joins the Board with a background in global finance, focusing on corporate finance and public company readiness [6]

家电丨市场观察 本周看点： -奔向AI的厨电战争，该为谁打响？ -阿里、小米们加速"围攻"Meta，AI眼镜打响"持久战"; -空间计算机很好， 但苹果、INAIR、魅族谁更接近未来？ 行业环境 1.奔向AI的厨电战争，该为谁打响？ 关键词 ： 厨房,年轻人,智能化,烹饪,户外经济 概要 ： 在消费格局变化下，厨房对年轻人吸引力减弱，中国厨电企业通过AI技术融合推出智 能化产品吸引用户，如"食神"大模型。但市场对其高溢价和数据安全问题态度不一。行业还面 临房地产下行、海外竞争等挑战，企业尝试多元化发展、优化设计并加速出海。未来，厨电企 业需拓展饮食产业链，借助AI赋能降低下厨门槛，重塑市场格局，把握智能化发展机遇。 2.阿里、小米们加速"围攻"Meta，AI眼镜打响"持久战" 关键词 ： AI眼镜,智能硬件,市场表现,供应链,佩戴体验 概要 ： 扎克伯格认为智能眼镜将成未来手机，2024年一季度全球销量达60万台，同比增长 216%，远超VR和AR。Meta引领行业，苹果等加速布局，但中国产品多停留在"PPT"阶段。AI 眼镜因成本低、佩戴舒适受青睐，预计2025年销量达550万台。然而，技术设计平衡、SKU ...

Core Insights - PharmaTher Holdings Ltd. is focused on developing ketamine-based therapies and supports the FDA's new Commissioner's National Priority Voucher (CNPV) program to expedite the regulatory review process for its products [1][2][7] - The CNPV program significantly reduces the review time for drug applications from approximately 10-12 months to 1-2 months, allowing for accelerated approval if legal requirements are met [2] - PharmaTher has a robust chemistry, manufacturing, and controls (CMC) package for its ketamine product, with an FDA approval goal date set for August 9, 2025 [3] Clinical Developments - The company has promising clinical data for its ketamine therapies targeting rare and near-rare disorders, including Parkinson's disease and Complex Regional Pain Syndrome [4] - PharmaTher is developing innovative delivery systems such as KETAPATCH™, a microneedle patch, and a wearable pump, which aim to provide easier administration compared to traditional intravenous infusions [4] Regulatory Designations - The FDA has granted five orphan drug designations to PharmaTher for ketamine treatments addressing conditions like Amyotrophic Lateral Sclerosis (ALS) and Rett Syndrome [5] - These designations highlight the company's commitment to addressing critical unmet medical needs, particularly in mental health and pain management [6] Strategic Positioning - PharmaTher aims to leverage the CNPV program to enhance its development timeline and deliver value to patients and shareholders, aligning with national health priorities [7] - The company is positioned to become a leader in the pharmaceutical development of ketamine through its focus on novel, intellectual property-protected delivery systems [7]

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly misleading investors about the company's business prospects during the period from February 16, 2023, to February 12, 2025 [1][2]. Allegations - The lawsuit claims that West Pharmaceutical failed to disclose significant ongoing destocking in its high-margin HVP portfolio, contrary to its assertions of strong customer demand [2]. - It is alleged that the SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2]. - The margin pressures faced by the company raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-standing customers [2]. - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2]. Disclosure of Truth - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to the loss of two major CGM customers transitioning to in-house manufacturing [3]. - West also indicated that its SmartDose devices would be margin dilutive in 2025 and mentioned that steps would be taken to improve the economics of the SmartDose [3]. - Following this announcement, West's stock price fell by $123.17 per share, a decline of approximately 38%, closing at $199.11 on February 13, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 7, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].